report summary
Cell gene therapy (CGT) has great potential, and the upstream CDMO industry is expected to usher in explosive growth
Investment and financing in the CGT field are rapidly heating up, and a large number of drugs under research have entered the clinic. As of October 2021, there are 1,890 CGT research projects (from preclinical to pre-registration, less than 400 in 2015). Due to complex technical mechanisms, high-threshold process development and large-scale production, strict regulatory requirements, and limited industrialization experience, CGT products are more dependent on CDMOs, and their outsourcing penetration rate exceeds 65% (traditional biological preparations 35%). The production of viral vectors as the core involves a very complex process, is extremely difficult, and has a long preparation cycle. It is expected that the outsourcing rate of CGT will remain high in the future.
It is estimated that in 2025, the global CGTCDMO market size will reach US$10.1 billion (5-year compound 35%), and the domestic market will reach 1.7 billion US dollars (5-year compound 51%). Due to the relatively large production capacity of CXO giants such as Lonza and WuXi AppTec, and the perfect GMP standards, it is expected that the dividends of the rapid development of the CDMO market will be shared by the major giants in the future.
The company has been sharpening its sword for ten years, focusing on industry difficulties and focusing on the development of carrier technology
The company started the gene therapy CRO business as early as 13 years ago, and built and perfected the basic technology platform required for early research and development of gene therapy through basic and pilot research. Since then, taking advantage of the development of the industry, Dongfeng has actively built a CDMO process team and built GMP production capacity, deployed CGT R&D and production of the whole industry chain business, and formed advanced production process development, quality control technology development and manufacturing level, as well as large-scale industrialization capabilities, comprehensive Ensure product quality and service capabilities are in the leading position in the industry.
Technological upgrades, production capacity enhancements, economies of scale, and rapid growth in operating income and profits
Thanks to the first-mover advantage in R&D and technology and the continuous improvement of project experience, the company’s order volume has increased year by year. Up to now, the company has implemented more than 100 projects with an amount of more than 650 million yuan. The revenue is expected to reach 250 million yuan, with a three-year compound growth rate of nearly 80%.
Abundant orders in hand, strong momentum for rapid growth
Up to now, the company has 23 projects in hand, with orders > 400 million yuan, covering many fields such as oncolytic virus, AAV and LV. Benefiting from the previous technology accumulation and project resource reserves, the company’s CDMO business, especially IND-CMC, has developed rapidly in recent years. Among them, the oncolytic virus projects serving Innovax and Finogen have entered Phase II clinical trials, and will contribute rich business in the future. order revenue. In addition, thanks to the early deployment of CRO service business, in-depth understanding of the development direction of cutting-edge technologies, and continuous accumulation of know-how, the company is expected to form a virtuous circle of mutual transformation between CRO and CDMO projects. At present, many CROs and preclinical projects will become the company’s Potential source of rapid growth in the future.
To view the full report click here
Note: The articles on this site have not been posted and shared by netizens or institutions unless they are marked as original. If there is any need for publicity or infringement, please contact [email protected].
This article is reprinted from: https://www.dx2025.com/archives/166663.html
This site is for inclusion only, and the copyright belongs to the original author.